Pages that link to "Q69735865"

The following pages link to IL-6/IFN-beta-2 as a circulating hormone. Induction by cytokine administration in humans (Q69735865):

Displaying 40 items.

• Endotoxin-induced tumor necrosis factor alpha synthesis in murine embryo fibroblasts. (Q33594509) (← links)
• Altered transcriptional regulation of phosphoenolpyruvate carboxykinase in rats following endotoxin treatment (Q34197420) (← links)
• Dysregulation of in vitro cytokine production by monocytes during sepsis (Q34211246) (← links)
• Amniotic fluid interleukin 6 in preterm labor. Association with infection (Q34249986) (← links)
• Interferon beta 2/interleukin 6 modulates synthesis of alpha 1-antitrypsin in human mononuclear phagocytes and in human hepatoma cells (Q34576820) (← links)
• Immunomodulatory agents in the laboratory and clinic (Q35224457) (← links)
• Regulatory effects of interleukin-6 in immunoglobulin G immune-complex-induced lung injury. (Q35763648) (← links)
• Interleukin-6 immunoreactivity in human tumors (Q35816757) (← links)
• Malaria mimicry with tumor necrosis factor. Contrasts between species of murine malaria and Plasmodium falciparum (Q35831427) (← links)
• Interleukin-6 serum level and monocyte production in head and neck cancer (Q35993599) (← links)
• Antitumor activity of recombinant interleukin 6 in mice (Q36350671) (← links)
• N-linked glycosylation is required for optimal function of Kaposi's sarcoma herpesvirus-encoded, but not cellular, interleukin 6 (Q36399250) (← links)
• Interleukin-6 and the acute phase response (Q36559880) (← links)
• On the mechanism for efficient repression of the interleukin-6 promoter by glucocorticoids: enhancer, TATA box, and RNA start site (Inr motif) occlusion (Q36732089) (← links)
• Cytokine profiles in localized scleroderma and relationship to clinical features (Q36784652) (← links)
• Endogenous tumor necrosis factor, interleukin-6, and gamma interferon levels during Listeria monocytogenes infection in mice (Q36957911) (← links)
• Experimental elimination of tumor necrosis factor in low-dose endotoxin models has variable effects on survival (Q36966855) (← links)
• Sex difference in link between interleukin-6 and stress (Q37147477) (← links)
• Interleukin-6 in clinical medicine (Q37189514) (← links)
• Rationale for immunotherapy of renal cell carcinoma (Q37803895) (← links)
• Interleukin-6 and its receptor during homeostasis, inflammation, and tumor growth (Q38232568) (← links)
• Host defense against infections and inflammations: role of the multifunctional IL-6/IFN-beta 2 cytokine (Q38650083) (← links)
• Uroepithelial cells are part of a mucosal cytokine network (Q39860504) (← links)
• Serum soluble interleukin 6 (IL-6) receptor and IL-6/soluble IL-6 receptor complex in systemic juvenile rheumatoid arthritis (Q40336418) (← links)
• Cytokine-mediated gene therapy for cancer (Q40589441) (← links)
• C1-inhibitor substitution therapy in septic shock and in the vascular leak syndrome induced by high doses of interleukin-2. (Q40684870) (← links)
• Monitoring of immunotherapy with cytokines or monoclonal antibodies (Q40689787) (← links)
• Interleukin 10 (IL-10) regulation of tumour necrosis factor alpha (TNF-alpha) from human alveolar macrophages and peripheral blood monocytes (Q41211455) (← links)
• IL-6 in malignant pleural effusions and its augmentation by intrapleural instillation of IL-2 (Q41627715) (← links)
• Mucosal tumour necrosis factor alpha and interleukin-6 in patients with Helicobacter pylori associated gastritis (Q41878177) (← links)
• Interleukin-1 beta and interleukin-6 release by peripheral blood monocytes in head and neck cancer (Q42390133) (← links)
• Cellular and cytokine responses of the human central nervous system to intracranial administration of tumor necrosis factor α for the treatment of malignant gliomas (Q42482850) (← links)
• Anti-TNF monoclonal antibodies prevent haemorrhage-induced suppression of Kupffer cell antigen presentation and MHC class II antigen expression (Q44541200) (← links)
• Interleukin 6 production by peripheral blood mononuclear cells in patients with chronic hepatitis B virus infection and primary biliary cirrhosis (Q45773875) (← links)
• Phase I trial with recombinant interleukin-2 (rIL-2): immune activation by rIL-2 alone or following pretreatment with recombinant interferon-gamma (Q56967327) (← links)
• Interleukin-6 and acute-phase proteins in head and neck cancer (Q60678860) (← links)
• Dose-dependent increase in plasma interleukin-6 after recombinant tumour necrosis factor infusion in humans (Q68640953) (← links)
• Interaction of interleukin-6, tumour necrosis factor and interleukin-1 during Listeria infection (Q71739906) (← links)
• The immunobiological effects of interleukin-2 in vivo (Q72790073) (← links)
• PEDV nsp16 negatively regulates innate immunity to promote viral proliferation (Q92229806) (← links)